**Table D-75. Evidence table for studies addressing management of PPH (Oleen 1990)**

| **Study** **Description** | **Intervention** | **Inclusion/Exclusion** **Criteria & Population** | **Outcomes** |
| --- | --- | --- | --- |
| Author:Oleen et al., 199076Country:USEnrollment period: Jan 1986 to March 1987Birth setting: HospitalsFacility characteristics: Multisite- 12 sitesFunding:Upjohn Company Design: Case series | **Intervention:** Carboprost tromethamine sterile solution (125 or 250 ug) intramuscular, intramyometrial, intravenous, intrauterine, or intracervical**Groups:****G1:** interventionN at enrollment: **G1:** 237 (blood loss could not be estimated for 10 cases)**G1a:** 215 success**G1b:** 12 failureDuration of treatment: NRTiming of treatment: NR Order of treatment: NRLength of follow-up: NR | **Operational definition of PPH:** NR**Definition of success of treatment**: Control of hemorrhage **Method of blood loss measurement:** NR**Severity:** NRInclusion criteria: * Receipt of carboprost tromethamine at a study hospital
* Data accessible in medical record

Exclusion criteria: * See inclusion

**Maternal age, yrs, mean ± SD:****G1:** 25.3 ± 5.7 **Parity, n:** Primiparous**G1:** 108Multiparous**G1:** 113Non-viable offspring**G1:** 15 **Weeks gestation:** NR**Single pregnancy:** NR**Multiple pregnancy:** NR**Race/ethnicity:** NR**BMI:** NR**Baseline hemoglobin:** NR**SES:** NR**Mode of birth, n:** Cesarean**G1:** 72 (30.4)**Risk factors, n (%):** Labor induction/augmentation**G1:** 92 (38.8)FibroidsPreeclampsia (magnesium treated)**G1:** 43 (18.1)**Primary etiology of PPH, n (%):** Chorioamnionitis**G1:** 3 (1.3)Retained products of conception**G1:** 27 (11.4)Lacerations**G1:** 35 (14.8)Peripheral coagulopathy**G1:** 4 (1.7) | **Cessation of hemorrhage, immediate, n (%):****G1:** 208/237 (87.8) **Cessation of hemorrhage, with further oxytocins:****G1:** 17/237**Therapy failed:****G1:** 12/237 (5.1) **Blood loss, ml mean (range):****G1:** 970 ± 955 (100-9500)**G1a:** 900 ± 748 (100-9500)**G1b:** 2229 ± 2454 (500-9500)**Transfusion:** RBC, n (%)**G1:** 64 (27)FFP, cryoprecipitate, or albumen, n (%)**G1:** 9 (4)**ICU admission:** NR**Anemia:** NR**Length of stay:** NR**Mortality:** NR**Uterine preservation:**Hysterectomy**G1:** 7**Future fertility:** NR**Breastfeeding:** NR**Psychological impact:** NR**Confounders:** NR **Effect modifiers:** NR**Harms pre-specified:** No**Harms, n (%):** Diarrhea**G1:** 27 (11.4)Elevated blood pressure**G1:** 16 (6.8)Vomiting**G1:** 16 (6.8)Elevated temperature**G1:** 5 (2.1)Flushing**G1:** 4 (1.7)Tachycardia**G1:** 4 (1.7)  |